Next Article in Journal
The Urgent Need for Dengue Vaccination: Combating an Escalating Public Health Crisis in Pakistan
Next Article in Special Issue
B and T Cell Bi-Cistronic Multiepitopic Vaccine Induces Broad Immunogenicity and Provides Protection Against SARS-CoV-2
Previous Article in Journal
Correction: Ziemssen et al. Immune Response to Initial and Booster SARS-CoV-2 mRNA Vaccination in Patients Treated with Siponimod—Final Analysis of a Nonrandomized Controlled Clinical Trial (AMA-VACC). Vaccines 2023, 11, 1374
Previous Article in Special Issue
T Cell Responses during Human Immunodeficiency Virus/Mycobacterium tuberculosis Coinfection
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Vaccines
Volume 12
Issue 8
10.3390/vaccines12080912
vaccines-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Follicular Immune Landscaping Reveals a Distinct Profile of FOXP3hiCD4hi T Cells in Treated Compared to Untreated HIV

by
Spiros Georgakis
1,†,
Michail Orfanakis
1,†,
Cloe Brenna
1,
Simon Burgermeister
1,
Perla M. Del Rio Estrada
2,3,
Mauricio González-Navarro
2,
Fernanda Torres-Ruiz
2,
Gustavo Reyes-Terán
4,
Santiago Avila-Rios
2,
Yara Andrea Luna-Villalobos
2,
Oliver Y. Chén
5,
Giuseppe Pantaleo
6,
Richard A. Koup
7 and
Constantinos Petrovas
1,*
1
Department of Laboratory Medicine and Pathology, Institute of Pathology, Lausanne University Hospital, University of Lausanne, Rue du Bugnon 25, CH-1011 Lausanne, Switzerland
2
Centro de Investigacion en Enfermedades Infecciosas, Instituto Nacional de Enfermedades Respiratorias “Ismael Cosio Villegas”, Mexico City 14080, Mexico
3
Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA
4
Institutos Nacionales de Salud y Hospitales de Alta Especialidad, Secretaría de Salud de México, Mexico City 14610, Mexico
5
Department of Laboratory Medicine and Pathology, Faculty of Biology and Medicine, Lausanne University Hospital, University of Lausanne, CH-1011 Lausanne, Switzerland
6
Service of Immunology and Allergy, Department of Medicine, Lausanne University Hospital, CH-1011 Lausanne, Switzerland
7
Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
*
Author to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Vaccines 2024, 12(8), 912; https://doi.org/10.3390/vaccines12080912
Submission received: 11 July 2024 / Revised: 7 August 2024 / Accepted: 8 August 2024 / Published: 12 August 2024
(This article belongs to the Special Issue Antiviral T and B Cell Immunity)
Browse Figures
Review Reports Versions Notes

Abstract

:
Follicular helper CD4hi T cells (TFH) are a major cellular pool for the maintenance of the HIV reservoir. Therefore, the delineation of the follicular (F)/germinal center (GC) immune landscape will significantly advance our understanding of HIV pathogenesis. We have applied multiplex confocal imaging, in combination with the relevant computational tools, to investigate F/GC in situ immune dynamics in viremic (vir-HIV), antiretroviral-treated (cART HIV) People Living With HIV (PLWH) and compare them to reactive, non-infected controls. Lymph nodes (LNs) from viremic and cART PLWH could be further grouped based on their TFH cell densities in high-TFH and low-TFH subgroups. These subgroups were also characterized by different in situ distributions of PD1hi TFH cells. Furthermore, a significant accumulation of follicular FOXP3hiCD4hi T cells, which were characterized by a low scattering in situ distribution profile and strongly correlated with the cell density of CD8hi T cells, was found in the cART-HIV low-TFH group. An inverse correlation between plasma viral load and LN GrzBhiCD8hi T and CD16hiCD15lo cells was found. Our data reveal the complex GC immune landscaping in HIV infection and suggest that follicular FOXP3hiCD4hi T cells could be negative regulators of TFH cell prevalence in cART-HIV.

1. Introduction

Despite the intense research in HIV pathogenesis and cure approaches over the last 40 years, several aspects related to relevant immune cell and viral dynamics are still not well understood. Combination antiretroviral therapy (cART) has extended the life expectancy and improved the quality of life of People Living With HIV (PLWH). Despite the blocking of HIV replication, cART cannot eradicate the virus [1,2]. The latent infection of resting CD4hi T cells is a main contributor to the lifelong persistence of HIV [3]. Integrated HIV DNA can be detected in blood and peripheral tissues, but recent studies suggest that genetically intact proviruses are mainly detected in the lymph nodes (LNs) [4]. Chronic HIV infection results in dramatic changes in LN architecture and the loss of stromal cells and adaptive immune cell responses [5]. Follicular helper CD4hi T cells (TFH), a pivotal mediator of efficient B cell responses to pathogens [6,7], represent a major contributor to the HIV reservoir within the central memory CD4hi T cell compartment [8,9]. Non-human primate (NHP) studies have shown an accumulation of TFH cells in chronically SIV-infected compared to non-infected animals, a profile associated with an increased frequency of activated germinal center B cells and secretion of SIV-specific antibodies [10]. Progression to AIDS (acquired immunodeficiency syndrome, advanced stage of disease) was associated with an advanced loss of TFH cells in SIV-infected NHPs [11]. In addition to TFH and GC B cell altered dynamics, chronic HIV/SIV results in the increased cell density of LN/follicular effector CD8hi/GrzBhiCD8hi T cells [12], deregulated immune-regulatory (TREG) and follicular immune-regulatory (TFR) CD4+ cells [13,14], the infiltration of inflammatory cell subsets and excessive fibrosis [5,15]. Foxp3hiCD4hi T cells were reported to suppress the capacity of TFH cells for proliferation and cytokine secretion, in ex vivo HIV-focused studies [14]. Additionally, the IL-10 and CTLA-4 expression of TFR cells were up-regulated in treatment-naïve PLWH [16]. Innate immune cells, which contribute to adaptive immune responses either by antigen presentation or by the secretion of immunomodulatory cytokines [17], play an important role in HIV pathogenesis [18,19], while their role in cure strategies [20] is a field under development.
Several studies have focused on the characterization of LN-derived T cells, mainly using LN-derived cell suspensions and flow or mass cytometry-based assays [21] or single-cell RNA analysis [22,23]. However, these experimental approaches lack information about immune cell spatial organization. The in situ characterization of immune cell types, using multiplex imaging methodologies and appropriate cohorts of control and disease samples, can provide important insights into the prevalence, phenotype, and spatial organization of the relevant immune cells in HIV, which could also indicate possible mechanistic interactions between specific cell types.
Herein, we applied multiplex imaging combined with advanced computational tools for the comprehensive characterization of immune landscaping in viremic and cART HIV LNs compared to reactive control LNs or tonsils from non-HIV infected individuals. Our results indicate that both viremic and cART HIV LNs can be further grouped based on TFH cell density. These groups exhibited distinct profiles of Foxp3hiCD4hi T, Granzyme B (GrzB)hiCD8hi T and innate immune cell subsets. Our work points to a possible role of FOXP3hiCD4hi T cells as regulators of TFH cells in HIV, particularly in cART individuals. Our neighboring analysis revealed a distinct distribution pattern for both TFH and follicular (F-)FOXP3hiCD4hi T between PLWH subgroups, as well as compared to non-infected donors.

2. Materials and Methods

2.1. Human Material

The tissue samples used in this study were obtained from (i) the Centro de Investigacion en Enfermedades Infecciosas (CIENI), Instituto Nacional de Enfermedades Respiratorias (INER) in Mexico City, Mexico (viremic LNs), (ii) the University of Washington, Seattle, WA, USA (cART HIV LNs) and (iii) the archives of the Institute of Pathology of Lausanne University Hospital, Switzerland (control LNs). Tonsillar tissues were obtained from anonymized children who underwent routine tonsillectomy at the Hospital de l’Enfance of Lausanne. All procedures were in accordance with the Declaration of Helsinki and approved by the appropriate Institutional Review Board/Ethical Committee: (i) all tissue samples from PWH were procured with explicit written informed consent from participants prior to donation, adhering strictly to the principles outlined in the Declaration of Helsinki.

2.2. Tissue Processing

Fresh tissues were fixed as soon as possible after biopsy for 16–24 h in formalin or 4% paraformaldehyde and processed for the preparation of formalin-fixed, paraffin-embedded (FFPE) blocks using standard procedures at the corresponding pathology departments. All downstream tissue processing was carried out in our laboratory. The blocks were sequentially cut into 4 μm sections and prepared on Superfrost glass slides (Thermo Scientific, Waltham, MA, USA, Ref. J1800AMNZ), dried overnight at 37 °C and stored at 4 °C. Before staining, the slides were heated on a metal hotplate (Stretching Table, MEDITE Medical GmbH, Burgdorf, Germany, OTS 40.2025, Ref. 9064740715) at 65 °C for 20 min. This melting step ensures the proper adherence and deparaffinization of the tissue section. Fluorescent multiplex immunohistochemistry (mIHC) staining was performed on the Ventana Discovery Ultra Autostainer from Roche Diagnostics (Ventana Medical Systems, Tucson, AZ, USA).

2.3. Confocal Imaging Assays

2.3.1. Tissue Staining and Data Acquisition

Tissue sections were sequentially subjected to antibody blocking using Opal blocking/antibody diluent solution (ARD1001EA) staining with primary antibodies (details on antibodies, clones and dilutions are listed in Supplementary Table S1), incubation with secondary HRP-labeled antibodies for 16 min, detection with optimized fluorescent Opal tyramide signal amplification (TSA) dyes (Opal 7-color Auto-mation IHC kit, from Akoya (Marlborough, MA, USA), Ref. NEL821001KT) and repeated antibody denaturation cycles. The samples were then counterstained with Spectral DAPI from Akoya for 4 min, rinsed in soapy water and mounted using DAKO mounting medium (Dako/Agilent, Santa Clara, CA, USA, Ref. S302380-2).
Images were acquired using a Leica Stellaris 8 SP8 confocal system, equipped with Leica Application Suite X (LAS-X)-4.6.1.27508 software, at 512 × 512 pixel density and 0.75× optical zoom using a 20× objective (NA), unless otherwise stated. Frame averaging or summing was never used while obtaining the images. At least 70% of each section was imaged, to ensure an accurate representation and minimize selection bias. Tissues stained with a single antibody–fluorophore combination were used to create a compensation matrix via the Leica LAS-AF Channel Dye Separation module (Leica Microsystems, Wetzlar, Germany), which was used to correct fluorophore spillover (when present), as per the user’s manual.

2.3.2. Quantitative Imaging Analysis (Histo-Cytometry)

A confocal image analysis was performed with Imaris software version 9.9.0 (Bitplane). Quantitative data were generated from the images through Histo-cytometry analysis [12,24], as previously reported. In brief, the Surface Creation module of Imaris was used to generate 3-dimensional segmented surfaces (based on the nuclear signal) of spillover-corrected images. Data generated from Histo-cytometry, such as average voxel intensities for all channels, in addition to the volume and sphericity of the 3-dimensional surfaces, were exported in Microsoft Excel format. The files were converted to comma separated value (.CVS) files, and the data were imported into FlowJo (version 10) to be further analyzed and quantitated. Well-defined areas devoid of background staining were included in the analysis, and the data were quantified either as relative frequencies or as cell counts normalized to the total follicular area screened. Optimal z-stack settings were applied in all collected images. Maximum Intensity Projections (MIPs) are presented throughout the manuscript.

2.3.3. Data Analysis–Neighboring Analysis

The distance between the relevant cell subsets (CD20hi, PD1hiCD57hi/lo etc.) was calculated with Python 3.10.9 using the SciPy library [25]. The matrix interaction was created using X and Y coordinates from each cell phenotype, and the median distance was extracted. Furthermore, to characterize the probability of observing different patterns of cellular distribution across Regions Of Interest (ROIs) and patients, we studied the curves generated from the Ripley’s G function and the theoretical Poisson curve using pointpats 2.3.0 (https://doi.org/10.5281/zenodo.7706219, accessed on 25 September 2023). The area between the empirical and theoretical Poisson curve was extracted using the NumPy library [26]. ROIs with at least 20 positive cells for each cell subset under investigation were analyzed. The data were presented as (i) bar graphs, showing the range of all the various distances measured (X axis) and the frequency or count of B cells that fell within each distance range and (ii) dot plots, where each dot represents the mean value of the minimum distances between two cell populations for each follicular area.

2.3.4. Viral Load Measurement

The m2000 system (Abbott, Abbot Park, IL, USA) was used to perform an automated real-time polymerase chain reaction (PCR) for the determination of HIV plasma viral load (pVL), with a detection limit of 40 HIV RNA copies/mL. Flow cytometry with the AQUIOS Tetra-1 Panel in AQUIOS CL (Beckman Coulter Life Sciences, Indianapolis, IN, USA) was used to determine CD4hi T cell counts. All PWLH involved in the current study were infected with clade B HIV.

2.4. Statistical Analysis

For the imaging data analysis, the Mann–Whitney test and simple linear regression analysis were used. The p-values of the Mann–Whitney test were corrected using the False Discovery Rate (FDR) correction test [27] with q = 0.05, for multiple comparisons (both uncorrected and corrected p values for each figure are shown in Supplementary Table S2). The analysis and graphs were generated using the GraphPad Prism 8.3.0 software. For statistical significance, a p value < 0.05 was considered.

3. Results

3.1. Similar Profiles of Follicular Helper CD4hi T Cell Densities in Viremic and cART HIV LNs

TFH cells are major contributors to HIV reservoir maintenance [28], as well as the development of broadly neutralizing antibodies [29]; we sought to investigate their in situ cell density in HIV-infected, compared to non-infected, tissues. We used tonsils and non-infected, cancer free, reactive LNs characterized by follicular hyperplasia as strict control groups (Figures S1 and S6) (Table 1). We started our analysis by employing a multiplex immunofluorescence imaging assay that allows for the simultaneous identification of major GC B and T cell subsets (Figure 1A). The gating strategy applied for the identification and quantitative analysis of relevant cell subsets by the Histo-cytometry pipeline [12,24] is shown (Figure 1B). The in situ density of CD20hi/dim cells was used for the identification of individual follicular areas (highly enriched in CD20hi/dim cells), as well as the ‘total follicular’ area (Figure 1B). As expected [5,30], PWLH tissues harbor both ‘preserved’ and ‘irregular’ follicular structures (Figure 1A and Figure S1B). CD4hi T cell subsets within the ‘total follicular’ area were analyzed based on their expression of PD1 and CD57 (Figure 1B). A preliminary analysis revealed low expression levels of CD4 in certain TFH cells, particularly the ones expressing CD57 (Figure S2A). Several studies have shown that TFH cells express a unique PD1hi phenotype [9,10,31] compared to other CD4hi T cells, while PD1 expression per cell (judged by Mean Fluorescence Intensity) of follicular CD8hi T cells is 4–5 times lower than that of TFH [12]. Therefore, the expression level of PD1 can serve as an in situ TFH identifier. To avoid inconsistencies and the misinterpretation of our data, especially for the CD57hi TFH cell subset, we chose to directly analyze the PD1hiCD57hi/low cells in GCs (Figure 1B). The gating for setting the threshold of these biomarkers is shown in Figure S2A. Their expression level in extrafollicular areas, as well as the manual inspection of their fluorescence intensities in the raw images, was used as a reference to set the cut-off for ‘high’ values. The backgating of PD1hi and CD57hi cells identified by Histo-cytometry (shown as spheres) to the original image showed a high concordance between the digitally identified cells and their original counterparts identified by immunofluorescence staining (Figure 1C).
The calculation of PD1hi cell densities (normalized cell counts per mm2) allowed for the further grouping of HIV viremic and cART tissues into two subgroups characterized by significantly different cell densities of PD1hi TFH cells: one with high PD1hi TFH cell densities (hereafter ‘high-TFH’) and one with low PD1hi TFH cell densities (hereafter ‘low-TFH’) (Figure 1D, left panel). To assess the heterogeneous (or not) prevalence of PD1hi TFH cells across an individual tissue, the cell densities of PD1hi TFH cells per follicle for every tissue were analyzed. A great variability in PD1hi TFH cells was observed in all tissues, particularly in tonsils and control LNs (Figure 1D, right panel).
Next, the expression of CD57, a carbohydrate epitope that marks a TFH cell subset with a distinct positioning and function in human LNs [32,33] was investigated. As expected [33], the PD1hiCD57hi group represents a subset of TFH cells (Figure 1E). PD1hiCD57hi TFH cells exhibited a similar cell density profile to PD1hi cells (Figure 1E) and a heterogenous prevalence across the tissue (Figure S2B). A strong correlation between PD1hi and PD1hiCD57hi TFH cell densities was found for tonsil, control and cART LNs (Figure 1F). This association was less significant in the high-TFH PLWH viremic subgroup (Figure 1F). Although not statistically significant, a negative association was observed between the PD1hi TFH cells and pVL in viremic PLWH, as well as a trend for a higher pVL in the low-TFH compared to high-TFH viremic PWLH subgroup (Figure 1G, lower and upper panel, respectively). Therefore, in agreement with our previous data for viremic SIV infection [10], two subgroups defined by significantly different cell densities of TFH cells were identified in viremic as well as cART HIV LNs.

3.2. A Distinct Positioning Profile of TFH Cells in HIV-Infected Compared to Non-Infected Tissues

Next, the spatial positioning of GC B cells and the TFH cell subsets was investigated in our tissue cohort. To this end, follicles from all groups, harboring at least 20 cells for each corresponding cell population, were used. The X, Y coordinates of the relevant cells were extracted (Figure 2A, upper panel), and a digitalized representation of their distribution was generated (Figure 2A, lower panel). Then, the ‘G function’ parameter, as a surrogate for the dispersion/scattering of a distribution, of a given cell type, as well as the mean values of the minimum distances between relevant cell types in individual follicular areas, was calculated [34]. An example of follicles with a low and high mean distance between CD20hi and PD1hi cells and their associated G parameters is shown (Figure 2B). A similar distribution profile for CD20hi cells among the tissue subgroups analyzed was detected (Figure 2C). Contrary to B cells, PD1hi cells expressed a significantly higher dispersion in the vir-HIV subgroups compared to control LNs (Figure 2D). Regarding the PD1hi cells distribution of cART tissues, a significant difference was found only between control and low-TFH cART LNs (Figure 2D). Furthermore, a significantly higher dispersion was found in low-TFH compared to high-TFH HIV tissues, in both viremic and cART tissues from PLWH (Figure 2D). A significantly higher mean of minimum distance between CD20hi and PD1hi cells was found in the vir- and cART HIV compared to control tissues (Figure 2E), while no difference was observed among the PLWH subgroups (Figure 2E).
Then, the aforementioned parameters were calculated for the PD1hiCD57lo and PD1hiCD57hi cells in all tissue groups. Given the low abundancy of CD57hi TFH cells, a significantly lower number of follicular areas, especially in the low-TFH HIV subgroups, was analyzed (Figure 2F,G). Again, a comparable CD20 G-function profile was found among the tissue groups in these follicular areas (Figure S3A). Our data showed a similar G function and distance profile between tonsils and reactive control LNs (Figure 2F,G). In general, PD1hiCD57lo and PD1hiCD57hi cells express a significantly higher degree of dispersion in HIV-infected tissues compared to tonsils and control LNs (Figure 2F). Interestingly, the cART low-TFH subgroup was the one with the highest dispersion of PD1hiCD57lo cells among the PLWH subgroups (Figure 2F). With respect to the mean minimum distance, a trend, which was statistically significant for many of the comparisons, for a longer distance between CD20hi and PD1hiCD57lo OR hi cells, was measured in HIV-infected tissues compared to tonsils and control LNs (Figure 2G). Our data suggest a distinct TFH cell in situ distribution profile, as well as a TFH-B cell proximity profile in PLWH, compared to tonsils and control LNs.

3.3. Significant Accumulation of Follicular Compared to Extrafollicular FOXP3hiCD4hi T Cells in cART Low-TFH LNs

We used the expression of FOXP3 as a surrogate for potential immune-regulatory CD4hi T cells (Figure 3A). The Histo-cytometry gating scheme for the identification and calculation of FOXP3hiCD4hi T cells in extrafollicular and intrafollicular areas (highly enriched in CD20hi/dim cells) is shown (Figure 3B). The concordance between digitally/Histo-cytometry-identified FOXP3hiCD4hi T cells (shown as spheres) and their original counterparts is demonstrated in Figure 3C. The lowest cell density of extrafollicular (EF) and follicular (F) FOXP3hiCD4hi T cells was found in tonsils and the highest in reactive control LNs (Figure 3D,E). Comparable EF-FOXP3hiCD4hi T cell densities among the PLWH subgroups were found (Figure 3D). Although not statistically significant, a trend for higher cell densities of F-FOXP3hiCD4hi T cells in cART, compared to vir-HIV, LNs was measured (Figure 2E). A broad range of F-FOXP3hiCD4hi T cell densities was observed, particularly in the cART low-TFH subgroup (Figure 2E and Figure S3B).
Next, the EF- and F-FOXP3hiCD4hi T cell densities were compared in each LN. Similar EF- and F-FOXP3hiCD4hi T cell densities were found in control LNs, while fewer F-FOXP3hiCD4hi compared to EF-FOXP3hiCD4hi T cells were found for almost all viremic PLWH tissues tested (Figure 3F). However, the opposite profile was observed for the cART tissues (Figure 3F). A consistent, significantly higher cell density of F-FOXP3hiCD4hi compared to EF-FOXP3hiCD4hi T cells was measured, especially in the cART low-TFH subgroup (Figure 3F). The distribution profile (G function) of FOXP3hiCD4hi T cells across the whole imaged area for each tissue was also investigated. No significant differences were found among the groups analyzed (Figure S3C). Then, we focused our analysis on F-FOXP3hiCD4hi T cells. An example of the identification and corresponding digital representation of their distribution in cART tissues is shown (Figure 3G). A significantly lower dispersion was measured in the cART low-TFH compared to the cART high-TFH subgroup, when the G factor was calculated for F-FOXP3hiCD4hi T cells (Figure 3H). Our data show a preferential accumulation of follicular immune regulatory CD4hi T cells in cART compared to viremic PLWH LNs.

3.4. LN GrzBhiCD8hi T Cells Are Negatively Associated with Blood Viral Load

The in situ profile of bulk and effector (GrzBhi)CD8hi T cells (Figure 4A) was investigated using a multiplex imaging assay, and the Histo-cytometry gating scheme is shown in Figure 4B. The applied antibody panel (Supplementary Table S2, panel II) does not include a follicular/GC biomarker; therefore, the cell density of the CD8hi T cell subsets was analyzed for the whole imaged area (Figure 4A,B). The concordance between digitally/Histo-cytometry-identified GrzBhiCD8hi T cells (shown as spheres) and their original counterparts is demonstrated in Figure 4C. In line with our previous data [12,15], an accumulation of bulk and GrzBhiCD8hi T cells was measured in viremic donors, particularly the high-TFH tissues, compared to tonsils and control LNs (Figure 4D and Figure S4A). Although not significant, a reduction in GrzBhiCD8hi T cells was observed between the viremic and cART tissues, which was more evident between the high-TFH subgroups (Figure 4D). A positive association between circulating and LN bulk as well as GrzBhiCD8hi T cells was found in HIV viremic samples (Figure S4B). Contrary to circulating CD8hi T cells (Figure S4C), a significant negative correlation was observed between the viral load and the LN GrzBhiCD8hi T cells (Figure 4E).
Next, the correlation between bulk and GrzBhiCD8hi as well as FOXP3hiCD4hi T cell densities was investigated. A significant association was observed between the two CD8hi T cell populations in viremic LNs (Figure S4D), as well as the cART low-TFH subgroup (Figure 4F). However, this was not the case for the cART high-TFH subgroup (Figure 4F). Among the groups analyzed, a positive correlation was found between bulk CD8hi and EF-FOXP3hiCD4hi T cell densities in the cART low-TFH subgroup (Figure 4G, upper panel). This correlation was statistically significant between bulk CD8hi T cells and F-FOXP3hiCD4hi T cells in the same subgroup (Figure 4G, lower panel). The distance profiling revealed a similar dispersion of GrzBhiCD8hi T cells in LNs from cART, compared to those from viremic PLWH (Figure 4H). Conclusively, our data revealed an accumulation of GrzBhiCD8hi T cells in PWLH LNs compared to non-infected tissues, which was inversely correlated with the viral load in viremic PLWH.

3.5. Differential Modulation of Innate Immune Cell Subsets by cART

HIV is a chronic disease characterized by immune activation and inflammation [5,35,36]. Given the role of the innate immunity in HIV pathogenesis, we sought to investigate the tissue dynamics of several innate immune cell subsets using relevant biomarkers (CD163 and CD68, markers for monocytes/macrophages [37]; CD15, a surrogate for myeloid cells/granulocytes; CD16, a surrogate for activated myeloid cells, neutrophils and NK cells [38,39]) (Figure 5A). The Histo-cytometry gating scheme for the identification and quantification of these cell subsets is shown in Figure 5B. In general, a reduction was measured for all innate immune cell subsets analyzed in low-, compared to high-TFH viremic, subgroups (Figure 5C), that was significant for CD15hiCD16lo cells (Figure 5C). With respect to cART, lower cell densities of CD163hiCD68lo, CD15hiCD16lo, CD16hiCD15lo and CD16hiCD15hi cells were found in cART high-TFH compared to viremic high-TFH tissues (Figure 5C). Comparable cell densities of CD68hiCD163lo cells were counted among all tissue groups analyzed (Figure 5C, upper panel).
Then, the relationship between CD8hi T cells and innate immunity cell types was investigated. A positive association between the CD68hi or CD163hi cell subsets and bulk CD8hi T cells in viremic LNs was found (Figure S5A). A significant positive correlation between CD16hiCD15lo and bulk or GrzbhiCD8hi T cells was found in the vir-HIV high-TFH group (Figure 5D). No such correlations were observed in cART LNs. Similar to GrzbhiCD8hi T cells, a significant inverse correlation was also observed between CD16hiCD15lo cells and peripheral blood viral load in viremic PLWH (Figure S5B). An analysis of the in situ distribution profiling showed a higher dispersion in cART compared to viremic HIV-infected tissues for CD163 hi cells, while comparable profiles were found for CD68hi and CD16hi cells (Figure S5C). Furthermore, a lower minimum mean distance between GrzBhiCD8hi and CD16hi cells, but not CD68hi or CD163hi, in viremic compared to cART HIV tissues was found (Figure 5E and Figure S5D). Altogether, our data suggest that the cell density of the individual innate cell types was differently affected in patients undergoing cART.

4. Discussion

Here, we have investigated the immune cell landscape in reactive LNs from PLWH and compared it to non-infected control LNs and tonsils (Figure S6). We chose to compare the in situ immune dynamics in HIV LNs to non-infected, reactive LNs characterized by active follicles (follicular hyperplasia), as a reference for highly active F/GCs. Given the abundance in GC of B and TFH cells, as well as the preservation of the follicular and sub-follicular structures, tonsils are considered as a ‘prototype’ lymphoid organ for the investigation of the F/GC immune cell types. We should emphasize that none of the viremic PLWH had active opportunistic infections or AIDS-defining pathologies at the time of the sampling. The time since diagnosis was also similar among the individuals. Our analysis revealed two subgroups of HIV-infected LNs with respect to the cell density of TFH cells, in both viremic and cART PLWH. This profile, at least for viremic individuals, is in line with the TFH cell dynamics in the SIV non-human primate model [10,11].
No association of TFH cell densities with gender, age, CD4hi and CD8hi counts was found in either viremic or cART PLWH. HIV infection of LN CD4hi T cells per se, intrinsic TFH cell factors and/or the interaction of TFH cells with the GC microenvironment represent potential mechanisms that could contribute to the observed TFH cell in situ dynamics by altering the differentiation and/or turnover rate of total (or specific subset) TFH cells in PLWH. Regarding the viremic PLWH, we observed a negative association between pVL and GC/TFH cells that could reflect a preferential infection/loss of TFH cells or a generalized loss of TFH cells in highly viremic PLWH. The relatively low numbers (~5% of TFH cells) of HIV DNA+ TFH cells [9] suggest that the HIV infection of TFH cells per se may not be responsible for this negative association. Similar infection rates for CD57hi and CD57lo TFH cells have been reported previously [40] challenging the preferential infection/loss of CD57hi TFH cells and the observed weaker association between these two TFH cell subsets in viremic compared to cART PLWH. Abortive HIV infection represents an alternative mechanism for the loss of CD4 T cells, at least in vitro [41]. The role of such mechanisms in the regulation of vir-HIV TFH cells needs to be investigated. Alternatively, progressive fibrosis and damage of vital LN structural elements (e.g., the Fibroblastic Reticular Cell network [42]) and/or the loss of GC survival signals (e.g., due to damage of the Follicular Dendritic Cell network [43]) for TFH cells in high viremics could affect the differentiation and maintenance or turnover of TFH cells. The observed heterogeneity of TFH cell densities in different follicles across an individual tissue indicates that the locality of such mechanisms is possibly an important factor to consider in future studies. Our data urge for further investigation of LN structure elements, in conjunction with the in situ dynamics of immune cell types. The development of appropriate imaging tools will greatly facilitate such efforts.
Two groups (LoViReT and HiViReT) of treated PLWH, harboring a relatively wide range of very low viral reservoirs, was recently described [44]. Whether the cART TFH subgroups correspond to a status is not known and merits further investigation. Despite viral control, cART is not able to fully restore the LN/follicular damage in PLWH back to normal. FRC reconstitution is one of the factors that could affect the reconstitution of the LN CD4hi T cell pool and presumably TFH cell prevalence [45]. No association of TFH cell densities with treatment duration was found. However, the capacity of individual PLWH to differentially respond to cART and restore relevant LN elements could contribute to the observed high- and low-TFH subgroups in the cART HIV group. Our distribution analysis showed an overall higher dispersion of PD1hi TFH cells in HIV-infected compared to non-infected tissues, which is also associated with a longer mean distance between TFH and B cells in the infected donors. Previous studies have shown a reciprocal regulation between TFH and GC B cells [46]. We hypothesize that the described spatial distribution profile may reflect a lower probability for these two cell subsets to interact in the infected LNs, leading to the subsequent loss of vital signals for TFH cells. The aforementioned profile was more evident in the low-TFH HIV subgroups, further supporting our hypothesis.
Follicular immune-regulatory CD4hi T cells (TFR) represent an important ‘microenvironment cell factor’ for the development of TFH cells [14,47,48]. Tonsils harbor the lowest number of FOXP3hiCD4hi T cells, in line with previous reports [47,49]. Our data revealed a contrasting profile regarding the cell density between EF- and F-FOXP3hiCD4hi T cells in control and viremic compared to cART-HIV LNs. Within the cART HIV group, we measured a significant increase in F-FOXP3hiCD4hi T, specifically in the cART-low TFH subgroup, suggesting a negative role for TFH cell development in these individuals. Supplementary to this is the significantly less scattered distribution of FOXP3hiCD4hi T cells within the follicles of low- compared to high-TFH cART tissues. Whether the FOXP3hi CD4 hi T cells represent bona fide TFR cells or cells originating from TFH cells [50] is not known and needs further investigation. Our data urge for a comprehensive in situ phenotypic and functional characterization of FOXP3hiCD4hi T cells, especially in cART-HIV PLWH.
In contrast to PLWH, the majority of CD8hi T cells in tonsils and control LNs express a GrzBlo phenotype, in line with our previous observations [12]. The positive association between the numbers circulating and LN CD8hi T cell density suggests that increased trafficking of bulk and presumably effector CD8hi T cells may support, at least in part, their increased cell density in viremic LNs. A CXCR3/CXCR3L-mediated mechanism, which has been previously proposed for HIV PLWH [51] and SIV-infected non-human primates [15], could contribute to the CD8hi T cell density profile we observed for viremic PLWH. Several studies have shown the role of CD8hi T cells in controlling HIV and SIV [52,53]. In line with these studies, we found a significant negative correlation between LN GrzBhi CD8hi T cells and pVL that indicates a potential role of GrzBhiCD8hi T cells in viral control, at least in part, in our cohort. An intermediate effector GrzBloGrzKhiTOXhiTCF1hiCD39hiCD8hi population negatively associated with plasma viremia was recently described in SIV/HIV-infected subjects [54]. One could hypothesize that different CD8hi T cell subsets can contribute to viral control. The relative impact of individual CD8hi subsets in viremic and cART PLWH is not known and needs further investigation. Therefore, the comprehensive in situ phenotypic (e.g., expression of homing receptors), functional (e.g., ‘regulatory’ function [55]) and spatial characterization of CD8hi T cell subsets, especially in cART-HIV PLWH, is of great interest, given their potential role for immunotherapies aiming to eliminate the virus. We found a positive correlation between CD8hi and F-FOXP3hiCD4hi T cells, specifically in the low-TFH cART-HIV subgroup. Whether and how these two cell types could affect the cell density of TFH cells in this group remains to be elucidated.
Overall, we observed a diverse profile of innate immunity cell types among the groups. Individual cell types were differentially modulated by cART, while no consistent association with the low- or high-TFH status was observed. We measured different cell densities for the CD68hiCD163hi and CD68loCD163hi cell subsets. CD163 is a receptor that can be cleaved, and therefore, the cell density of CD163hi macrophages/monocytes can be underestimated. Our results, however, indicate that the possible cleavage/loss of CD163 is not responsible for the observed in situ dynamics [44]. Our data point to a diverse innate immune LN microenvironment that could affect the host–virus interplay in these LNs [18]. We found a strong correlation between LN CD8hi T cells and CD16hiCD15lo cells in high-TFH viremic tissues. This profile was also associated with (i) a less dispersed CD8hi T cell distribution, (ii) a shorter distance between CD8hi and CD16hi cells and (iii) a negative association between pVL and LN CD8hi or CD16hiCD15lo cells. These findings urge for further investigation of neutrophils/granulocytes, in addition to macrophages, as possible key determinants for innate immunity/CD8hi T cell crosstalk and virus dynamics [56]. Whether the same or different innate immune cell subsets mediate the host–virus interaction in viremic and cART PLWH is not known and remains to be elucidated.
Altogether, we have analyzed several immunological cell types in a well-characterized cohort of LNs and provide evidence (i) for the subgrouping of HIV-infected LNs (both from viremic and cART PLWH) based on their TFH cell density, (ii) of a distinct profile of potential immunosuppressive FOXP3hiCD4hi T cells in cART LNs with respect to their cell densities, distribution between extrafollicular and follicular areas and spatial distribution within the follicular compartment, and (iii) the effect of cART on the cell density of CD8hi T and innate immune cells (Table 2). Altered TFH cell density in HIV subgroups is associated with different CD8hi and F-FOXP3hiCD4hi T cell density and distribution profiles, too. The data suggest that further investigation of CD8hi and immune-regulatory CD4hi T cells could provide insights for the TFH cell prevalence in HIV and particularly in cART PLWH. Understanding the follicular/GC microenvironment in HIV infection could further illuminate the role of TFH cells in HIV pathogenesis and possible combinatorial interventions aiming to manipulate a major HIV tissue reservoir.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/vaccines12080912/s1, Table S1. Antibodies used for confocal imaging. Table S2. Mann–Whitney test-generated p values were corrected using FDR correction with q = 0.05. Figure S1. (A) Representative whole-tissue examples of CD20 (red), PD1 (green) and DAPI (blue) staining pattern from control tonsils, control LNs, vir HIV LNs and cART HIV LNs (scale bar: 300 μm). (B) Representative examples of CD20 (red), CD4 (green), DAPI (blue), CD57 (gray) and PD1 (cyan) staining pattern from a cART HIV LN (scale bar: 30 μm). The white line denotes the follicular area. Figure S2. (A) Immunophenotyping gating strategy used for the identification of TFH cells in lymphoid and tonsillar tissues of interest, based on the expression of PD1 and CD57, by Histo-cytometry. The extrafollicular expression level was used for setting the gates identifying the PD1 and CD57 subsets. An example from one LN and one tonsil is shown. (B) Dot plot graph showing the normalized numbers of PD1hiCD57hi TFH cells in all groups. Each symbol represents a follicular area. Figure S3. (A) Bar graph showing the G function values for CD20hi B cells in all groups of tissues (control tonsils (N = 29), control LNs (N = 29), HIV vir-high TFH (N = 13), HIV vir-low TFH (N = 5), HIV cART-high TFH (N = 11) and HIV cART-low TFH (N = 7)). (B) Dot graph showing the distribution of normalized FOXP3hi CD4hi cell counts in tonsils, control LNs, vir HIV LNs and cART HIV LNs. Each symbol represents a follicle. (C) Bar graph showing the G function values for total FOXP3hi CD4hi T cells in control and HIV-infected LNs (control LNs (N = 5), HIV vir-high TFH (N = 6), HIV vir-low TFH (N = 6), HIV cART-high TFH (N = 6) and HIV cART-low TFH (N = 11)). Each symbol represents a donor. Figure S4. (A) Bar graphs demonstrating the frequency of bulk CD8+ (upper panel) and GrzBhi CD8+ (lower panel) cells in control tonsils (N = 5), control LNs (N = 5), HIV vir-high TFH (N = 6), HIV vir-low TFH (N = 6), HIV cART-high TFH (N = 6) and HIV cART-low TFH (N = 14). Each symbol represents a different donor. (B) Linear regression analysis between circulating CD8+ T cell frequencies and LN bulk or GrzBhi CD8+ T cells in viremic PLWH. (C) Linear regression analysis between blood viral loads and frequencies of circulating CD8+ T cells in viremic PLWH. (D) Linear regression analysis between LN bulk and GrzBhi CD8+ T cells in HIV viremic high- and low-TFH subgroups. Figure S5. (A) Linear regression analysis to show the correlation between LN CD68hiCD163hi (upper panel) or CD68hiCD163lo (lower panel) cells and LN CD8hi cells in HIV vir LNs. (B) Linear regression analysis to show the correlation between LN CD16hiCD15lo and blood viral load in viremic PLWH. (C) Bar graphs showing the calculated G function values for CD163hi (HIV vir-high TFH (N = 6), HIV vir-low TFH (N = 5), HIV cART-high TFH (N = 5) and HIV cART-low TFH (N = 10)), CD68hi (HIV vir-high TFH (N = 6), HIV vir-low TFH (N = 5), HIV cART-high TFH (N = 5) and HIV cART-low TFH (N = 10)) and CD16hi (HIV vir-high TFH (N = 6), HIV vir-low TFH (N = 3), HIV cART-high TFH (N = 4) and HIV cART-low TFH (N = 10)) LN cells in HIV subgroups. (D) Bar graphs showing the mean values of the minimum distances between GrzBhi CD8hi T cells and CD68hi (left panel) or CD163hi (right panel) cells in the HIV subgroups (HIV vir-high TFH (N = 6), HIV vir-low TFH (N = 5), HIV cART-high TFH (N = 5) and HIV cART-low TFH (N = 10)). Each symbol represents a different donor. Figure S6. Hematoxylin and eosin (H&E) staining for all the LN tissues used in this study (scale bar: 1.5 mm).

Author Contributions

S.G. and M.O. performed experiments, analyzed and interpreted data and drafted the manuscript; C.B. and S.B. performed distance analysis; O.Y.C. supervised the statistical analysis; P.M.D.R.E., M.G.-N., F.T.-R., G.R.-T., S.A.-R., Y.A.L.-V., G.P. and R.A.K. provided tissue material, clinical data and input for the data interpretation; C.P. conceived, designed and supervised the study, interpreted data and revised the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding

These studies were supported by grants from the Swiss National Science Foundation (SNF, 310030_204226 to C.P.) and in part by the National Institute of Health (USA 7UM AI164561 to C.P.) and the Intramural Research Program of NIAID.

Institutional Review Board Statement

All procedures were in accordance with the Declaration of Helsinki and approved by the appropriate Institutional Review Board/Ethical Committee. The utilization of these samples was formally sanctioned by (i) both the Research Committee and the Ethics in Research Committee of the National Institute of Respiratory Diseases “Ismael Cosío Villegas,” Mexico City, as part of the “C71-18” protocol, (ii) the University of Washington (study ID: STUDY00001091, CR ID:CR00004042) and (iii) the Canton de Vaud-CER-VD, Switzerland for LNs (2021-01161) and tonsils (PB_2016-02436 (201/11)). Written informed consent was obtained from all participants.

Informed Consent Statement

Informed consent was obtained from all subjects involved in the study.

Data Availability Statement

The authors agree to share all publication-related data. Presented data are accessible through https://doi.org/10.5281/zenodo.12579627 (accessed on 25 September 2023) and used scripts are uploaded on https://github.com/LTI-CHUV/Distance-Analysis (accessed on 25 September 2023). For further information, please contact the corresponding author at konstantinos.petrovas@chuv.ch.

Acknowledgments

The authors would like to thank Laurence de Leval for assisting with control lymph nodes and Natalie Piazzon (operational director of the Tissue Biobank), Damien Maison and Emilie Lingre, Institute of Pathology, CHUV, for their help with the tissue processing.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Dey, B.; Berger, E.A. Towards an HIV cure based on targeted killing of infected cells: Different approaches against acute versus chronic infection. Curr. Opin. HIV AIDS 2015, 10, 207–213. [Google Scholar] [CrossRef] [PubMed]
  2. Maldarelli, F. The role of HIV integration in viral persistence: No more whistling past the proviral graveyard. J. Clin. Investig. 2016, 126, 438–447. [Google Scholar] [CrossRef] [PubMed]
  3. De Flora, S.; Serra, D.; Basso, C.; Zanacchi, P. Mechanistic aspects of chromium carcinogenicity. Arch. Toxicol. Suppl. 1989, 13, 28–39. [Google Scholar] [CrossRef] [PubMed]
  4. Dufour, C.; Ruiz, M.J.; Pagliuzza, A.; Richard, C.; Shahid, A.; Fromentin, R.; Ponte, R.; Cattin, A.; Wiche Salinas, T.R.; Salahuddin, S.; et al. Near full-length HIV sequencing in multiple tissues collected postmortem reveals shared clonal expansions across distinct reservoirs during ART. Cell Rep. 2023, 42, 113053. [Google Scholar] [CrossRef]
  5. Estes, J.D. Pathobiology of HIV/SIV-associated changes in secondary lymphoid tissues. Immunol. Rev. 2013, 254, 65–77. [Google Scholar] [CrossRef] [PubMed]
  6. Mudd, P.A.; Minervina, A.A.; Pogorelyy, M.V.; Turner, J.S.; Kim, W.; Kalaidina, E.; Petersen, J.; Schmitz, A.J.; Lei, T.; Haile, A.; et al. SARS-CoV-2 mRNA vaccination elicits a robust and persistent T follicular helper cell response in humans. Cell 2022, 185, 603–613.e15. [Google Scholar] [CrossRef] [PubMed]
  7. Noto, A.; Suffiotti, M.; Joo, V.; Mancarella, A.; Procopio, F.A.; Cavet, G.; Leung, Y.; Corpataux, J.M.; Cavassini, M.; Riva, A.; et al. The deficiency in Th2-like Tfh cells affects the maturation and quality of HIV-specific B cell response in viremic infection. Front. Immunol. 2022, 13, 960120. [Google Scholar] [CrossRef] [PubMed]
  8. Aid, M.; Dupuy, F.P.; Moysi, E.; Moir, S.; Haddad, E.K.; Estes, J.D.; Sekaly, R.P.; Petrovas, C.; Ribeiro, S.P. Follicular CD4 T Helper Cells As a Major HIV Reservoir Compartment: A Molecular Perspective. Front. Immunol. 2018, 9, 895. [Google Scholar] [CrossRef]
  9. Perreau, M.; Savoye, A.L.; De Crignis, E.; Corpataux, J.M.; Cubas, R.; Haddad, E.K.; De Leval, L.; Graziosi, C.; Pantaleo, G. Follicular helper T cells serve as the major CD4 T cell compartment for HIV-1 infection, replication, and production. J. Exp. Med. 2013, 210, 143–156. [Google Scholar] [CrossRef]
  10. Petrovas, C.; Yamamoto, T.; Gerner, M.Y.; Boswell, K.L.; Wloka, K.; Smith, E.C.; Ambrozak, D.R.; Sandler, N.G.; Timmer, K.J.; Sun, X.; et al. CD4 T follicular helper cell dynamics during SIV infection. J. Clin. Investig. 2012, 122, 3281–3294. [Google Scholar] [CrossRef]
  11. Xu, H.; Wang, X.; Malam, N.; Lackner, A.A.; Veazey, R.S. Persistent Simian Immunodeficiency Virus Infection Causes Ultimate Depletion of Follicular Th Cells in AIDS. J. Immunol. 2015, 195, 4351–4357. [Google Scholar] [CrossRef] [PubMed]
  12. Petrovas, C.; Ferrando-Martinez, S.; Gerner, M.Y.; Casazza, J.P.; Pegu, A.; Deleage, C.; Cooper, A.; Hataye, J.; Andrews, S.; Ambrozak, D.; et al. Follicular CD8 T cells accumulate in HIV infection and can kill infected cells in vitro via bispecific antibodies. Sci. Transl. Med. 2017, 9, eaag2285. [Google Scholar] [CrossRef] [PubMed]
  13. Graff-Dubois, S.; Rouers, A.; Moris, A. Impact of Chronic HIV/SIV Infection on T Follicular Helper Cell Subsets and Germinal Center Homeostasis. Front. Immunol. 2016, 7, 501. [Google Scholar] [CrossRef] [PubMed]
  14. Miles, B.; Miller, S.M.; Folkvord, J.M.; Kimball, A.; Chamanian, M.; Meditz, A.L.; Arends, T.; McCarter, M.D.; Levy, D.N.; Rakasz, E.G.; et al. Follicular regulatory T cells impair follicular T helper cells in HIV and SIV infection. Nat. Commun. 2015, 6, 8608. [Google Scholar] [CrossRef] [PubMed]
  15. Ferrando-Martinez, S.; Moysi, E.; Pegu, A.; Andrews, S.; Nganou Makamdop, K.; Ambrozak, D.; McDermott, A.B.; Palesch, D.; Paiardini, M.; Pavlakis, G.N.; et al. Accumulation of follicular CD8+ T cells in pathogenic SIV infection. J. Clin. Investig. 2018, 128, 2089–2103. [Google Scholar] [CrossRef] [PubMed]
  16. Zhao, S.; Xu, W.; Tu, B.; Hong, W.G.; Zhang, Z.; Chen, W.W.; Zhao, M. Alterations of the frequency and functions of follicular regulatory T cells and related mechanisms in HIV infection. J. Infect. 2020, 81, 776–784. [Google Scholar] [CrossRef] [PubMed]
  17. Luster, A.D. The role of chemokines in linking innate and adaptive immunity. Curr. Opin. Immunol. 2002, 14, 129–135. [Google Scholar] [CrossRef] [PubMed]
  18. Jiang, S.; Chan, C.N.; Rovira-Clave, X.; Chen, H.; Bai, Y.; Zhu, B.; McCaffrey, E.; Greenwald, N.F.; Liu, C.; Barlow, G.L.; et al. Combined protein and nucleic acid imaging reveals virus-dependent B cell and macrophage immunosuppression of tissue microenvironments. Immunity 2022, 55, 1118–1134.e8. [Google Scholar] [CrossRef] [PubMed]
  19. Banga, R.; Procopio, F.A.; Lana, E.; Gladkov, G.T.; Roseto, I.; Parsons, E.M.; Lian, X.; Armani-Tourret, M.; Bellefroid, M.; Gao, C.; et al. Lymph node dendritic cells harbor inducible replication-competent HIV despite years of suppressive ART. Cell Host Microbe 2023, 31, 1714–1731.e9. [Google Scholar] [CrossRef]
  20. Board, N.L.; Moskovljevic, M.; Wu, F.; Siliciano, R.F.; Siliciano, J.D. Engaging innate immunity in HIV-1 cure strategies. Nat. Rev. Immunol. 2022, 22, 499–512. [Google Scholar] [CrossRef]
  21. Neidleman, J.; Luo, X.; Frouard, J.; Xie, G.; Hsiao, F.; Ma, T.; Morcilla, V.; Lee, A.; Telwatte, S.; Thomas, R.; et al. Phenotypic analysis of the unstimulated in vivo HIV CD4 T cell reservoir. Elife 2020, 9, e60933. [Google Scholar] [CrossRef] [PubMed]
  22. Davis, J.M. Keeping the ill at ease. Postgrad. Med. 1990, 88, 44–48. [Google Scholar] [CrossRef] [PubMed]
  23. Szabo, P.A.; Levitin, H.M.; Miron, M.; Snyder, M.E.; Senda, T.; Yuan, J.; Cheng, Y.L.; Bush, E.C.; Dogra, P.; Thapa, P.; et al. Single-cell transcriptomics of human T cells reveals tissue and activation signatures in health and disease. Nat. Commun. 2019, 10, 4706. [Google Scholar] [CrossRef] [PubMed]
  24. Moysi, E.; Del Rio Estrada, P.M.; Torres-Ruiz, F.; Reyes-Teran, G.; Koup, R.A.; Petrovas, C. In Situ Characterization of Human Lymphoid Tissue Immune Cells by Multispectral Confocal Imaging and Quantitative Image Analysis; Implications for HIV Reservoir Characterization. Front. Immunol. 2021, 12, 683396. [Google Scholar] [CrossRef] [PubMed]
  25. Virtanen, P.; Gommers, R.; Oliphant, T.E.; Haberland, M.; Reddy, T.; Cournapeau, D.; Burovski, E.; Peterson, P.; Weckesser, W.; Bright, J.; et al. SciPy 1.0: Fundamental algorithms for scientific computing in Python. Nat. Methods 2020, 17, 261–272. [Google Scholar] [CrossRef] [PubMed]
  26. Harris, C.R.; Millman, K.J.; van der Walt, S.J.; Gommers, R.; Virtanen, P.; Cournapeau, D.; Wieser, E.; Taylor, J.; Berg, S.; Smith, N.J.; et al. Array programming with NumPy. Nature 2020, 585, 357–362. [Google Scholar] [CrossRef] [PubMed]
  27. Lovell, D.P. Biological importance and statistical significance. J. Agric. Food Chem. 2013, 61, 8340–8348. [Google Scholar] [CrossRef]
  28. Miles, B.; Connick, E. TFH in HIV Latency and as Sources of Replication-Competent Virus. Trends Microbiol. 2016, 24, 338–344. [Google Scholar] [CrossRef] [PubMed]
  29. Havenar-Daughton, C.; Lee, J.H.; Crotty, S. Tfh cells and HIV bnAbs, an immunodominance model of the HIV neutralizing antibody generation problem. Immunol. Rev. 2017, 275, 49–61. [Google Scholar] [CrossRef]
  30. Biberfeld, P.; Ost, A.; Porwit, A.; Sandstedt, B.; Pallesen, G.; Bottiger, B.; Morfelt-Mansson, L.; Biberfeld, G. Histopathology and immunohistology of HTLV-III/LAV related lymphadenopathy and AIDS. Acta Pathol. Microbiol. Immunol. Scand. A 1987, 95, 47–65. [Google Scholar] [CrossRef]
  31. Crotty, S. Follicular helper CD4 T cells (TFH). Annu. Rev. Immunol. 2011, 29, 621–663. [Google Scholar] [CrossRef] [PubMed]
  32. Kim, C.H.; Rott, L.S.; Clark-Lewis, I.; Campbell, D.J.; Wu, L.; Butcher, E.C. Subspecialization of CXCR5+ T cells: B helper activity is focused in a germinal center-localized subset of CXCR5+ T cells. J. Exp. Med. 2001, 193, 1373–1381. [Google Scholar] [CrossRef]
  33. Padhan, K.; Moysi, E.; Noto, A.; Chassiakos, A.; Ghneim, K.; Perra, M.M.; Shah, S.; Papaioannou, V.; Fabozzi, G.; Ambrozak, D.R.; et al. Acquisition of optimal TFH cell function is defined by specific molecular, positional, and TCR dynamic signatures. Proc. Natl. Acad. Sci. USA 2021, 118, e2016855118. [Google Scholar] [CrossRef]
  34. Parra, E.R. Methods to Determine and Analyze the Cellular Spatial Distribution Extracted From Multiplex Immunofluorescence Data to Understand the Tumor Microenvironment. Front. Mol. Biosci. 2021, 8, 668340. [Google Scholar] [CrossRef] [PubMed]
  35. Brenchley, J.M.; Price, D.A.; Schacker, T.W.; Asher, T.E.; Silvestri, G.; Rao, S.; Kazzaz, Z.; Bornstein, E.; Lambotte, O.; Altmann, D.; et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat. Med. 2006, 12, 1365–1371. [Google Scholar] [CrossRef] [PubMed]
  36. Hunt, P.W.; Lee, S.A.; Siedner, M.J. Immunologic Biomarkers, Morbidity, and Mortality in Treated HIV Infection. J. Infect. Dis. 2016, 214 (Suppl. S2), S44–S50. [Google Scholar] [CrossRef]
  37. Austermann, J.; Roth, J.; Barczyk-Kahlert, K. The Good and the Bad: Monocytes’ and Macrophages’ Diverse Functions in Inflammation. Cells 2022, 11, 1979. [Google Scholar] [CrossRef] [PubMed]
  38. Yeap, W.H.; Wong, K.L.; Shimasaki, N.; Teo, E.C.; Quek, J.K.; Yong, H.X.; Diong, C.P.; Bertoletti, A.; Linn, Y.C.; Wong, S.C. CD16 is indispensable for antibody-dependent cellular cytotoxicity by human monocytes. Sci. Rep. 2016, 6, 34310. [Google Scholar] [CrossRef]
  39. McKenna, E.; Mhaonaigh, A.U.; Wubben, R.; Dwivedi, A.; Hurley, T.; Kelly, L.A.; Stevenson, N.J.; Little, M.A.; Molloy, E.J. Neutrophils: Need for Standardized Nomenclature. Front. Immunol. 2021, 12, 602963. [Google Scholar] [CrossRef]
  40. Boritz, E.A.; Darko, S.; Swaszek, L.; Wolf, G.; Wells, D.; Wu, X.; Henry, A.R.; Laboune, F.; Hu, J.; Ambrozak, D.; et al. Multiple Origins of Virus Persistence during Natural Control of HIV Infection. Cell 2016, 166, 1004–1015. [Google Scholar] [CrossRef]
  41. Doitsh, G.; Cavrois, M.; Lassen, K.G.; Zepeda, O.; Yang, Z.; Santiago, M.L.; Hebbeler, A.M.; Greene, W.C. Abortive HIV infection mediates CD4 T cell depletion and inflammation in human lymphoid tissue. Cell 2010, 143, 789–801. [Google Scholar] [CrossRef] [PubMed]
  42. Zeng, M.; Smith, A.J.; Wietgrefe, S.W.; Southern, P.J.; Schacker, T.W.; Reilly, C.S.; Estes, J.D.; Burton, G.F.; Silvestri, G.; Lifson, J.D.; et al. Cumulative mechanisms of lymphoid tissue fibrosis and T cell depletion in HIV-1 and SIV infections. J. Clin. Investig. 2011, 121, 998–1008. [Google Scholar] [CrossRef] [PubMed]
  43. Zhang, Z.Q.; Schuler, T.; Cavert, W.; Notermans, D.W.; Gebhard, K.; Henry, K.; Havlir, D.V.; Gunthard, H.F.; Wong, J.K.; Little, S.; et al. Reversibility of the pathological changes in the follicular dendritic cell network with treatment of HIV-1 infection. Proc. Natl. Acad. Sci. USA 1999, 96, 5169–5172. [Google Scholar] [CrossRef] [PubMed]
  44. Galvez, C.; Urrea, V.; Dalmau, J.; Jimenez, M.; Clotet, B.; Monceaux, V.; Huot, N.; Leal, L.; Gonzalez-Soler, V.; Gonzalez-Cao, M.; et al. Extremely low viral reservoir in treated chronically HIV-1-infected individuals. EBioMedicine 2020, 57, 102830. [Google Scholar] [CrossRef]
  45. Zeng, M.; Southern, P.J.; Reilly, C.S.; Beilman, G.J.; Chipman, J.G.; Schacker, T.W.; Haase, A.T. Lymphoid tissue damage in HIV-1 infection depletes naive T cells and limits T cell reconstitution after antiretroviral therapy. PLoS Pathog. 2012, 8, e1002437. [Google Scholar] [CrossRef] [PubMed]
  46. Baumjohann, D.; Preite, S.; Reboldi, A.; Ronchi, F.; Ansel, K.M.; Lanzavecchia, A.; Sallusto, F. Persistent antigen and germinal center B cells sustain T follicular helper cell responses and phenotype. Immunity 2013, 38, 596–605. [Google Scholar] [CrossRef] [PubMed]
  47. Sayin, I.; Radtke, A.J.; Vella, L.A.; Jin, W.; Wherry, E.J.; Buggert, M.; Betts, M.R.; Herati, R.S.; Germain, R.N.; Canaday, D.H. Spatial distribution and function of T follicular regulatory cells in human lymph nodes. J. Exp. Med. 2018, 215, 1531–1542. [Google Scholar] [CrossRef]
  48. Chowdhury, A.; Del Rio Estrada, P.M.; Tharp, G.K.; Trible, R.P.; Amara, R.R.; Chahroudi, A.; Reyes-Teran, G.; Bosinger, S.E.; Silvestri, G. Decreased T Follicular Regulatory Cell/T Follicular Helper Cell (TFH) in Simian Immunodeficiency Virus-Infected Rhesus Macaques May Contribute to Accumulation of TFH in Chronic Infection. J. Immunol. 2015, 195, 3237–3247. [Google Scholar] [CrossRef]
  49. Amodio, D.; Cotugno, N.; Macchiarulo, G.; Rocca, S.; Dimopoulos, Y.; Castrucci, M.R.; De Vito, R.; Tucci, F.M.; McDermott, A.B.; Narpala, S.; et al. Quantitative Multiplexed Imaging Analysis Reveals a Strong Association between Immunogen-Specific B Cell Responses and Tonsillar Germinal Center Immune Dynamics in Children after Influenza Vaccination. J. Immunol. 2018, 200, 538–550. [Google Scholar] [CrossRef]
  50. Jacobsen, J.T.; Hu, W.; TB, R.C.; Solem, S.; Galante, A.; Lin, Z.; Allon, S.J.; Mesin, L.; Bilate, A.M.; Schiepers, A.; et al. Expression of Foxp3 by T follicular helper cells in end-stage germinal centers. Science 2021, 373, eabe5146. [Google Scholar] [CrossRef]
  51. Brainard, D.M.; Tager, A.M.; Misdraji, J.; Frahm, N.; Lichterfeld, M.; Draenert, R.; Brander, C.; Walker, B.D.; Luster, A.D. Decreased CXCR3+ CD8 T cells in advanced human immunodeficiency virus infection suggest that a homing defect contributes to cytotoxic T-lymphocyte dysfunction. J. Virol. 2007, 81, 8439–8450. [Google Scholar] [CrossRef] [PubMed]
  52. Collins, D.R.; Gaiha, G.D.; Walker, B.D. CD8+ T cells in HIV control, cure and prevention. Nat. Rev. Immunol. 2020, 20, 471–482. [Google Scholar] [CrossRef] [PubMed]
  53. Policicchio, B.B.; Cardozo-Ojeda, E.F.; Xu, C.; Ma, D.; He, T.; Raehtz, K.D.; Sivanandham, R.; Kleinman, A.J.; Perelson, A.S.; Apetrei, C.; et al. CD8+ T cells control SIV infection using both cytolytic effects and non-cytolytic suppression of virus production. Nat. Commun. 2023, 14, 6657. [Google Scholar] [CrossRef] [PubMed]
  54. Strongin, Z.; Raymond Marchand, L.; Deleage, C.; Pampena, M.B.; Cardenas, M.A.; Beusch, C.M.; Hoang, T.N.; Urban, E.A.; Gourves, M.; Nguyen, K.; et al. Distinct SIV-specific CD8+ T cells in the lymph node exhibit simultaneous effector and stem-like profiles and are associated with limited SIV persistence. Nat. Immunol. 2024, 25, 1245–1256. [Google Scholar] [CrossRef] [PubMed]
  55. Miles, B.; Miller, S.M.; Folkvord, J.M.; Levy, D.N.; Rakasz, E.G.; Skinner, P.J.; Connick, E. Follicular Regulatory CD8 T Cells Impair the Germinal Center Response in SIV and Ex Vivo HIV Infection. PLoS Pathog. 2016, 12, e1005924. [Google Scholar] [CrossRef]
  56. Di Pilato, M.; Palomino-Segura, M.; Mejias-Perez, E.; Gomez, C.E.; Rubio-Ponce, A.; D’Antuono, R.; Pizzagalli, D.U.; Perez, P.; Kfuri-Rubens, R.; Benguria, A.; et al. Neutrophil subtypes shape HIV-specific CD8 T-cell responses after vaccinia virus infection. NPJ Vaccines 2021, 6, 52. [Google Scholar] [CrossRef]
Vaccines 12 00912 g001
Figure 1. Similar in situ cell density of TFH cells in viremic and cART PLWH LNs. (A) Representative examples of CD20 (red), CD4 (green), DAPI (blue), CD57 (gray) and PD1 (cyan) staining pattern from tonsil and control viremic and cART HIV LNs (scale bar: 30 μm). (B) The Histo-cytometry gating scheme used for the identification of TFH cell subsets based on their expression of PD1 and CD57 is shown. F and EF areas were manually identified based on the density of the CD20 signal, and the relevant cell counts were extracted for specific tissue localities. (C) Histo-cytometry-identified PD1hiCD57hi TFH cells were backgated to the original image using Imaris software. Each sphere represents one cell. (D) Bar graph (left) demonstrating the cell density (normalized per mm2 counts) of follicular PD1hi TFH cells in tonsils (N = 5), control LNs (N = 5), viremic HIV (N = 12) and cART HIV LNs (N = 20). Viremic and cART were further subdivided based on their TFH counts (HIV vir-high TFH (N = 6), HIV vir-low-TFH (N = 6), HIV cART-high-TFH (N = 6) and HIV cART-low-TFH (N = 14)). Each symbol represents one donor. The p values were calculated using the Mann–Whitney test and were corrected using FDR correction with q = 0.05 (Supplementary Table S2). Dot graph (right) shows the distribution of PD1hi cell densities among the samples. Each symbol represents a follicle. (E) Bar graph demonstrating the normalized per mm2 numbers of follicular PD1hiCD57hi TFH cells in the same groups/subgroups of the samples. (F) Linear regression analysis to address the correlation between PD1hi and PD1hiCD57hi absolute follicular counts between different subgroups. Each symbol represents a follicle. R-squared and p-values are displayed on graphs. (G) Linear regression analysis (lower) to address the correlation between normalized follicular PD1hi counts and blood viral load—pVL. Dot graph (upper) showing the pVL differences (as a log scale) between the viremic HIV subgroups.
Figure 1. Similar in situ cell density of TFH cells in viremic and cART PLWH LNs. (A) Representative examples of CD20 (red), CD4 (green), DAPI (blue), CD57 (gray) and PD1 (cyan) staining pattern from tonsil and control viremic and cART HIV LNs (scale bar: 30 μm). (B) The Histo-cytometry gating scheme used for the identification of TFH cell subsets based on their expression of PD1 and CD57 is shown. F and EF areas were manually identified based on the density of the CD20 signal, and the relevant cell counts were extracted for specific tissue localities. (C) Histo-cytometry-identified PD1hiCD57hi TFH cells were backgated to the original image using Imaris software. Each sphere represents one cell. (D) Bar graph (left) demonstrating the cell density (normalized per mm2 counts) of follicular PD1hi TFH cells in tonsils (N = 5), control LNs (N = 5), viremic HIV (N = 12) and cART HIV LNs (N = 20). Viremic and cART were further subdivided based on their TFH counts (HIV vir-high TFH (N = 6), HIV vir-low-TFH (N = 6), HIV cART-high-TFH (N = 6) and HIV cART-low-TFH (N = 14)). Each symbol represents one donor. The p values were calculated using the Mann–Whitney test and were corrected using FDR correction with q = 0.05 (Supplementary Table S2). Dot graph (right) shows the distribution of PD1hi cell densities among the samples. Each symbol represents a follicle. (E) Bar graph demonstrating the normalized per mm2 numbers of follicular PD1hiCD57hi TFH cells in the same groups/subgroups of the samples. (F) Linear regression analysis to address the correlation between PD1hi and PD1hiCD57hi absolute follicular counts between different subgroups. Each symbol represents a follicle. R-squared and p-values are displayed on graphs. (G) Linear regression analysis (lower) to address the correlation between normalized follicular PD1hi counts and blood viral load—pVL. Dot graph (upper) showing the pVL differences (as a log scale) between the viremic HIV subgroups.
Vaccines 12 00912 g001
Vaccines 12 00912 g002
Figure 2. A highly scattered distribution of TFH cells in HIV-infected compared to non-infected lymphoid tissues. (A) Representative immunofluorescence images showing the distribution of CD20hi (blue) and PD1hi (red) cells in follicles from one control, one vir-HIV high-TFH and one cART HIV high-TFH tissue (scale bar: 30 μm). The corresponding digitalized (generated by the Python distance analysis script) images are shown too. (B) The distribution bar graphs for the minimum distance between CD20hi and PD1hi cells in two follicular areas (control—left, cART—right) (upper panel). Diagrams showing the theoretical (blue) and experimental (red) Poisson curves for the distribution of PD1hi cells in two follicular areas (control—left, cART—right) (lower panel). Bar graphs showing the G function analysis for total CD20hi (C) and PD1hi TFH cells (D) in individual follicles from control and infected LNs (control LNs (N = 54), vir-HIV high-TFH (N = 42), vir-HIV low-TFH (N = 51), cART HIV high-TFH (N = 31) and cART HIV low-TFH (N = 55)). (E) The mean of minimum distance values between CD20hi and PD1hi cells in individual follicles from control and infected LNs is shown (control LNs (N = 54), vir-HIV high-TFH (N = 42), vir-HIV low-TFH (N = 51), cART HIV high-TFH (N = 31) and cART HIV low-TFH (N = 55)). (F) The G function analysis for PD1hiCD57hi (left) and PD1hiCD57lo (right) TFH cells in tonsils, control and infected LNs is shown (tonsils (N = 29), control LNs (N = 29), vir-HIV high-TFH (N = 13), vir-HIV low-TFH (N = 5), cART HIV high-TFH (N = 11) and cART HIV low-TFH (N = 7)). (G) Bar graphs showing the mean of minimum distances between CD20hi and PD1hiCD57lo (left) or PD1hiCD57hi (right) TFH cells in tonsils, control and infected LNs (tonsils (N = 29), control LNs (N = 29), vir-HIV high-TFH (N = 13), vir-HIV low-TFH (N = 5), cART HIV high-TFH (N = 11) and cART HIV low-TFH (N = 7)). Each dot represents one follicle in all presented graphs. The p values were calculated using the Mann–Whitney test and were corrected using FDR correction with q = 0.05 (Supplementary Table S2).
Figure 2. A highly scattered distribution of TFH cells in HIV-infected compared to non-infected lymphoid tissues. (A) Representative immunofluorescence images showing the distribution of CD20hi (blue) and PD1hi (red) cells in follicles from one control, one vir-HIV high-TFH and one cART HIV high-TFH tissue (scale bar: 30 μm). The corresponding digitalized (generated by the Python distance analysis script) images are shown too. (B) The distribution bar graphs for the minimum distance between CD20hi and PD1hi cells in two follicular areas (control—left, cART—right) (upper panel). Diagrams showing the theoretical (blue) and experimental (red) Poisson curves for the distribution of PD1hi cells in two follicular areas (control—left, cART—right) (lower panel). Bar graphs showing the G function analysis for total CD20hi (C) and PD1hi TFH cells (D) in individual follicles from control and infected LNs (control LNs (N = 54), vir-HIV high-TFH (N = 42), vir-HIV low-TFH (N = 51), cART HIV high-TFH (N = 31) and cART HIV low-TFH (N = 55)). (E) The mean of minimum distance values between CD20hi and PD1hi cells in individual follicles from control and infected LNs is shown (control LNs (N = 54), vir-HIV high-TFH (N = 42), vir-HIV low-TFH (N = 51), cART HIV high-TFH (N = 31) and cART HIV low-TFH (N = 55)). (F) The G function analysis for PD1hiCD57hi (left) and PD1hiCD57lo (right) TFH cells in tonsils, control and infected LNs is shown (tonsils (N = 29), control LNs (N = 29), vir-HIV high-TFH (N = 13), vir-HIV low-TFH (N = 5), cART HIV high-TFH (N = 11) and cART HIV low-TFH (N = 7)). (G) Bar graphs showing the mean of minimum distances between CD20hi and PD1hiCD57lo (left) or PD1hiCD57hi (right) TFH cells in tonsils, control and infected LNs (tonsils (N = 29), control LNs (N = 29), vir-HIV high-TFH (N = 13), vir-HIV low-TFH (N = 5), cART HIV high-TFH (N = 11) and cART HIV low-TFH (N = 7)). Each dot represents one follicle in all presented graphs. The p values were calculated using the Mann–Whitney test and were corrected using FDR correction with q = 0.05 (Supplementary Table S2).
Vaccines 12 00912 g002
Vaccines 12 00912 g003
Figure 3. Preferential accumulation of FOXP3hiCD4hi T cells in cART HIV follicular areas. (A) Representative examples of CD20 (red), CD4 (green), DAPI (blue) and FOXP3 (yellow) staining pattern from tonsil and control viremic and cART HIV LNs (scale bar: 30 μm). (B) Histo-cytometry immunophenotyping gating strategy used for the sequential identification of FOXP3hiCD4hi T cells in follicular and extrafollicular areas in a control LN (C) Representative backgating of Histo-cytometry-identified FOXP3hiCD4hi T cells, using Imaris software. Each sphere represents one cell. (D) Bar graph (left) demonstrating the normalised per mm2 counts of extrafollicular FOXP3hiCD4hi T cells in tonsils (N = 5), control LNs (N = 5), HIV vir-high-TFH (N = 6), HIV vir-low-TFH (N = 6), HIV cART-high-TFH (N = 6) and HIV cART-low-TFH (N = 14). (E) Bar graph showing the normalised per mm2 counts of follicular FOXP3hiCD4hi T cells in the same tissue samples. Each symbol represents one donor. (F) Bar graph with connecting lines demonstrating the normalized per mm2 counts of FOXP3hiCD4hi T cells in follicular and extrafollicular regions in each tissue analyzed. (G) Representative immunofluorescence images showing the distribution of FOXP3hi (green) and CD20hi (red) cells in follicles from one cART-high-TFH and one cART-low-TFH tissue. The corresponding digitalized (generated by the Python distance analysis script) images are shown too. (H) Bar graph showing the calculated G function values for follicular FOXP3hiCD4hi T cells in cART-high TFH (blue circles) and cART-low TFH (blue triangles) tissues (HIV cART-high TFH (N = 22) and HIV cART-low TFH (N = 64)). The p values were calculated using the Mann–Whitney test and were corrected using FDR correction with q = 0.05 (Supplementary Table S2).
Figure 3. Preferential accumulation of FOXP3hiCD4hi T cells in cART HIV follicular areas. (A) Representative examples of CD20 (red), CD4 (green), DAPI (blue) and FOXP3 (yellow) staining pattern from tonsil and control viremic and cART HIV LNs (scale bar: 30 μm). (B) Histo-cytometry immunophenotyping gating strategy used for the sequential identification of FOXP3hiCD4hi T cells in follicular and extrafollicular areas in a control LN (C) Representative backgating of Histo-cytometry-identified FOXP3hiCD4hi T cells, using Imaris software. Each sphere represents one cell. (D) Bar graph (left) demonstrating the normalised per mm2 counts of extrafollicular FOXP3hiCD4hi T cells in tonsils (N = 5), control LNs (N = 5), HIV vir-high-TFH (N = 6), HIV vir-low-TFH (N = 6), HIV cART-high-TFH (N = 6) and HIV cART-low-TFH (N = 14). (E) Bar graph showing the normalised per mm2 counts of follicular FOXP3hiCD4hi T cells in the same tissue samples. Each symbol represents one donor. (F) Bar graph with connecting lines demonstrating the normalized per mm2 counts of FOXP3hiCD4hi T cells in follicular and extrafollicular regions in each tissue analyzed. (G) Representative immunofluorescence images showing the distribution of FOXP3hi (green) and CD20hi (red) cells in follicles from one cART-high-TFH and one cART-low-TFH tissue. The corresponding digitalized (generated by the Python distance analysis script) images are shown too. (H) Bar graph showing the calculated G function values for follicular FOXP3hiCD4hi T cells in cART-high TFH (blue circles) and cART-low TFH (blue triangles) tissues (HIV cART-high TFH (N = 22) and HIV cART-low TFH (N = 64)). The p values were calculated using the Mann–Whitney test and were corrected using FDR correction with q = 0.05 (Supplementary Table S2).
Vaccines 12 00912 g003
Vaccines 12 00912 g004
Figure 4. Accumulated LN GrzBhiCD8hi T cells are negatively associated with PLWH blood viral load. (A) Representative examples of GRZb (red), CD8 (green) and DAPI (blue) staining pattern from tonsil and control vir HIV and cART HIV LNs (scale bar: 30 μm). (B) Histo-cytometry gating strategy used for the sequential identification of bulk CD8hi and GrzBhiCD8hi T cells. (C) Representative backgating of Histo-cytometry-identified GrzBhiCD8hi cells using Imaris software. Each sphere represents one cell. (D) Bar graph (upper) demonstrating the normalized per mm2 counts of bulk CD8hi cells in tonsils (N = 5), control LNs (N = 5), vir-HIV high-TFH (N = 6), vir-HIV low-TFH (N = 6), cART HIV high-TFH (N = 6) and cART HIV low-TFH (N = 14). Bar graph (lower) showing the normalized per mm2 counts of GrzBhiCD8hi T cells in the same tissue samples. Each symbol represents one donor. (E) Linear regression analysis showing the correlation between LN CD8hi (upper panel) and LN GrzBhiCD8hi (lower panel) normalized T cell counts with blood viral load. (F) Linear regression analysis showing the correlation between LN CD8hi and LN GrzBhiCD8hi T cell counts in cART HIV high-TFH (upper panel) and cART HIV low-TFH (lower panel). (G) Linear regression analysis to address the correlation between extrafollicular (upper panel) and follicular (lower panel) FOXP3hiCD4hi and LN CD8hi normalized T cell counts in cART HIV low-TFH subgroup. (H) Bar graph showing the G function values for LN GrzBhiCD8hi T cells in the HIV subgroups (vir-HIV high-TFH (N = 6), vir-HIV low-TFH (N = 5), cART HIV high-TFH (N = 6) and cART HIV low-TFH (N = 10)). The p values were calculated using the Mann–Whitney test and corrected using FDR correction with q = 0.05 (Supplementary Table S2).
Figure 4. Accumulated LN GrzBhiCD8hi T cells are negatively associated with PLWH blood viral load. (A) Representative examples of GRZb (red), CD8 (green) and DAPI (blue) staining pattern from tonsil and control vir HIV and cART HIV LNs (scale bar: 30 μm). (B) Histo-cytometry gating strategy used for the sequential identification of bulk CD8hi and GrzBhiCD8hi T cells. (C) Representative backgating of Histo-cytometry-identified GrzBhiCD8hi cells using Imaris software. Each sphere represents one cell. (D) Bar graph (upper) demonstrating the normalized per mm2 counts of bulk CD8hi cells in tonsils (N = 5), control LNs (N = 5), vir-HIV high-TFH (N = 6), vir-HIV low-TFH (N = 6), cART HIV high-TFH (N = 6) and cART HIV low-TFH (N = 14). Bar graph (lower) showing the normalized per mm2 counts of GrzBhiCD8hi T cells in the same tissue samples. Each symbol represents one donor. (E) Linear regression analysis showing the correlation between LN CD8hi (upper panel) and LN GrzBhiCD8hi (lower panel) normalized T cell counts with blood viral load. (F) Linear regression analysis showing the correlation between LN CD8hi and LN GrzBhiCD8hi T cell counts in cART HIV high-TFH (upper panel) and cART HIV low-TFH (lower panel). (G) Linear regression analysis to address the correlation between extrafollicular (upper panel) and follicular (lower panel) FOXP3hiCD4hi and LN CD8hi normalized T cell counts in cART HIV low-TFH subgroup. (H) Bar graph showing the G function values for LN GrzBhiCD8hi T cells in the HIV subgroups (vir-HIV high-TFH (N = 6), vir-HIV low-TFH (N = 5), cART HIV high-TFH (N = 6) and cART HIV low-TFH (N = 10)). The p values were calculated using the Mann–Whitney test and corrected using FDR correction with q = 0.05 (Supplementary Table S2).
Vaccines 12 00912 g004
Vaccines 12 00912 g005
Figure 5. Altered innate immunity signatures among control and HIV samples. (A) Representative examples of DAPI (blue), CD15 (cyan), CD16 (magenta), CD163 (yellow) and CD68 (red) staining pattern from tonsil and control vir-HIV and cART-HIV LNs (scale bar: 30 μm). (B) Histo-cytometry gating strategy used for the sequential identification of CD15hi, CD16hi, CD163hi and CD68hi innate cells. (C) Bar graphs demonstrating the normalized per mm2 counts of bulk CD68hiCD163lo (upper left), CD68loCD163hi (upper middle), CD68hiCD163hi (upper right), CD15hiCD16lo (lower left), CD15hiCD16lo (lower middle) and CD15hiCD16lo (lower right) in tonsils (N = 5), control LNs (N = 5), vir-HIV high-TFH (N = 6), vir-HIV low-TFH (N = 6), cART HIV high-TFH (N = 6) and cART HIV low-TFH (N = 14). Each symbol represents one donor. (D) Linear regression analysis to address the correlation between CD8hi (upper panel) or GrzBhiCD8hi (lower panel) T cells and CD16hiCD15lo cells in vir-HIV high-TFH tissues. (E) Bar graph showing the mean values of the minimum distances between GrzBhiCD8hi T and CD16hi cells in tissues from the HIV subgroups vir-HIV high-TFH (N = 6), vir-HIV low-TFH (N = 3), cART HIV high-TFH (N = 4) and cART HIV low-TFH (N = 10). Each dot represents a different donor. The p values were calculated using the Mann–Whitney test, and p values were corrected using FDR correction with q = 0.05 (Supplementary Table S2).
Figure 5. Altered innate immunity signatures among control and HIV samples. (A) Representative examples of DAPI (blue), CD15 (cyan), CD16 (magenta), CD163 (yellow) and CD68 (red) staining pattern from tonsil and control vir-HIV and cART-HIV LNs (scale bar: 30 μm). (B) Histo-cytometry gating strategy used for the sequential identification of CD15hi, CD16hi, CD163hi and CD68hi innate cells. (C) Bar graphs demonstrating the normalized per mm2 counts of bulk CD68hiCD163lo (upper left), CD68loCD163hi (upper middle), CD68hiCD163hi (upper right), CD15hiCD16lo (lower left), CD15hiCD16lo (lower middle) and CD15hiCD16lo (lower right) in tonsils (N = 5), control LNs (N = 5), vir-HIV high-TFH (N = 6), vir-HIV low-TFH (N = 6), cART HIV high-TFH (N = 6) and cART HIV low-TFH (N = 14). Each symbol represents one donor. (D) Linear regression analysis to address the correlation between CD8hi (upper panel) or GrzBhiCD8hi (lower panel) T cells and CD16hiCD15lo cells in vir-HIV high-TFH tissues. (E) Bar graph showing the mean values of the minimum distances between GrzBhiCD8hi T and CD16hi cells in tissues from the HIV subgroups vir-HIV high-TFH (N = 6), vir-HIV low-TFH (N = 3), cART HIV high-TFH (N = 4) and cART HIV low-TFH (N = 10). Each dot represents a different donor. The p values were calculated using the Mann–Whitney test, and p values were corrected using FDR correction with q = 0.05 (Supplementary Table S2).
Vaccines 12 00912 g005
Table 1. Demographic and clinical information of study PLWH.
Table 1. Demographic and clinical information of study PLWH.
ID
(cART-HIV)		AgeGenderAnatomic LocationCD4hi Counts
(Cells/μL)		Log pVL
(Copies/mL)		Years HIV+Treatment Duration
(Years)		Current ART
Regimen
cART-LN152MInguinal708ND6.55EVG/COBI/3TC/TAF
cART-LN260MInguinal864ND2222DTG/DESCOVY
cART-LN356FInguinal437ND2315DTG/DESCOVY
cART-LN467FInguinal1168ND107.5Biktarvy
cART-LN553FInguinal454ND2611Triumeq
cART-LN653MInguinal271ND914DVC/COBI/TRV
cART-LN750MInguinal849ND3215Genvova
cART-LN859MInguinal587ND1010Atripla
cART-LN963MInguinal276<40144RPV/DRV/RTV/DTG
cART-LN1052MInguinal459ND131ABC/3TC/DTG
cART-LN1146MInguinal493ND33EVT/COBI/3TC/TDF
cART-LN1265MInguinal476ND2625FPV/RTV/3TC/TDF/MVC
cART-LN1354FInguinal459ND131ABC/3TC/DTG
cART-LN1444MInguinal545ND167ATV/RTV/FTC/TDF
cART-LN1533MInguinal1121ND3y 5mo2y 1moEVG/COBI/FTC/TDF
cART-LN1651MInguinal805ND1710DTG/FTC/TDF
cART-LN1737MInguinal662ND54EFV/FTC/TDF
cART-LN1853MInguinal441ND2210DTG/FTC/TDF
cART-LN1957MInguinal500<402917DRV/RTV/ABC/FTC/TDF
cART-LN2058MInguinal636ND1915DRV/RTV/FTC/TDF
ID
(Viremic-HIV)		AgeGenderAnatomic LocationCD4hi Counts
(cells/μL)		CD8hi Counts
(cells/μL)		Treatment Duration
(years)		Log pVL
(copies/mL)
HIV-LN127MCervical520175No treatment5.26
HIV-LN220MCervical290881No treatment7
HIV-LN329MInguinal545830No treatment5.41
HIV-LN422MCervical476465No treatment5.75
HIV-LN537MInguinal3911158No treatment6.25
HIV-LN624MInguinal4533623No treatment6.84
HIV-LN729MCervical347756No treatment7
HIV-LN833MCervical4992211No treatment6.06
HIV-LN931MInguinal2812142No treatment6.29
HIV-LN1035MCervical4912284No treatment4.49
HIV-LN1127MCervical7191831No treatment4.69
HIV-LN1228MCervical7772195No treatment4.49
ID (Reactive LNs)AgeGenderAnatomic
Location
LN174MAxillary
LN241MCervical
LN321FCervical
LN449MInguinal
LN525FInguinal
Table 2. A table summarizing the main comparisons, with respect to cell densities, for immune cell subsets among the tissue groups. The relative prevalence of a given cell subset is denoted as VL= very low, L = low, H = high and VH = very high, among the groups.
Table 2. A table summarizing the main comparisons, with respect to cell densities, for immune cell subsets among the tissue groups. The relative prevalence of a given cell subset is denoted as VL= very low, L = low, H = high and VH = very high, among the groups.
PD1hi TFHPD1hiCD57hi TFHFOXP3hiCD4hi (Follicular)CD8hi (Entire LN)GrzBhiCD8hi (Entire LN)CD68hiCD163lo
(Entire LN)		CD68loCD163hi
(Entire LN)		CD15hiCD16lo
(Entire LN)		CD15loCD16hi
(Entire LN)
TonsilsHHVLLVLLHVLVL
Control LNsVHHHLVLLHVLVL
High-TFH viremicHLLHLLHLL
Low-TFH viremicLLLLLLHVLVL
High-TFH cARTHLLLVLLLVLVL
Low-TFH cARTLLHLVLLLVLVL
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Georgakis, S.; Orfanakis, M.; Brenna, C.; Burgermeister, S.; Del Rio Estrada, P.M.; González-Navarro, M.; Torres-Ruiz, F.; Reyes-Terán, G.; Avila-Rios, S.; Luna-Villalobos, Y.A.; et al. Follicular Immune Landscaping Reveals a Distinct Profile of FOXP3hiCD4hi T Cells in Treated Compared to Untreated HIV. Vaccines 2024, 12, 912. https://doi.org/10.3390/vaccines12080912

AMA Style

Georgakis S, Orfanakis M, Brenna C, Burgermeister S, Del Rio Estrada PM, González-Navarro M, Torres-Ruiz F, Reyes-Terán G, Avila-Rios S, Luna-Villalobos YA, et al. Follicular Immune Landscaping Reveals a Distinct Profile of FOXP3hiCD4hi T Cells in Treated Compared to Untreated HIV. Vaccines. 2024; 12(8):912. https://doi.org/10.3390/vaccines12080912

Chicago/Turabian Style

Georgakis, Spiros, Michail Orfanakis, Cloe Brenna, Simon Burgermeister, Perla M. Del Rio Estrada, Mauricio González-Navarro, Fernanda Torres-Ruiz, Gustavo Reyes-Terán, Santiago Avila-Rios, Yara Andrea Luna-Villalobos, and et al. 2024. "Follicular Immune Landscaping Reveals a Distinct Profile of FOXP3hiCD4hi T Cells in Treated Compared to Untreated HIV" Vaccines 12, no. 8: 912. https://doi.org/10.3390/vaccines12080912

APA Style

Georgakis, S., Orfanakis, M., Brenna, C., Burgermeister, S., Del Rio Estrada, P. M., González-Navarro, M., Torres-Ruiz, F., Reyes-Terán, G., Avila-Rios, S., Luna-Villalobos, Y. A., Chén, O. Y., Pantaleo, G., Koup, R. A., & Petrovas, C. (2024). Follicular Immune Landscaping Reveals a Distinct Profile of FOXP3hiCD4hi T Cells in Treated Compared to Untreated HIV. Vaccines, 12(8), 912. https://doi.org/10.3390/vaccines12080912

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop